TITLE

Apitope Raises €10M for its MS Drug Phase II Trial

PUB. DATE
November 2008
SOURCE
Bioworld Week;11/3/2008, Vol. 16 Issue 44, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Apitope Ltd. has raised €10 million from Belgian investors to carry out its Phase II proof-of-concept trial of peptide-based immunotherapy for multiple sclerosis. This move is part of the firm's formal venture capital funding round. The spur to put together the Belgian syndicate is an approach to Apitope from the University of Hasselt. The money will also be used to advance the firm's second product, a hemophilia treatment.
ACCESSION #
35064708

 

Related Articles

  • Apitope Raises €10M to Push its MS Drug to Phase II Trial. Moran, Nuala // BioWorld International;10/29/2008, Vol. 13 Issue 44, p1 

    The article reports on the efforts of Apitope Ltd. to raise €10 million from Belgian investors in its first formal venture capital funding round. The money will allow the company to carry out a Phase II proof-of-concept trial of its peptide-based immunotherapy for multiple sclerosis and to...

  • Apitope Raises €10M to Push its MS Drug to Phase II Trial. Moran, Nuala // BioWorld Today;10/29/2008, Vol. 19 Issue 211, p3 

    The article reports on the first formal venture capital funding round by Apitope Ltd. Proceeds from the funding round amounting to $12.5 million will be used by the company to start a Phase II proof-of-concept trial of its peptide-based immunotherapy for multiple sclerosis. Part of it will also...

  • Apitope Technology: MS vaccine shows promise in Phase I/IIa.  // PharmaWatch: CNS;Mar2008, Vol. 7 Issue 3, p6 

    The article reports on the results of the open label phase I/IIa trial of Apitope Technology Ltd.'s ATC-MS-1467 vaccine. The trial was designed as a dose-escalation study to assess the vaccine's safety and tolerability in six multiple sclerosis patients. Immunological results showed a...

  • Relapsing-Remitting Multiple Sclerosis: What is the Potential for Combination Therapy? Mäurer, M.; Rieckmann, P. // BioDrugs;2000, Vol. 13 Issue 3, p149 

    Multiple sclerosis is now a treatable disease and several immunomodulating therapies exist, but their clinical efficacy is moderate and treatment failure during the course of the disease is an increasing problem. As agents with different targets are available, the question was raised whether...

  • No Exit. Vittore, Vince // Telephony;1/27/2003, Vol. 244 Issue 2, p28 

    Focuses on the funding distribution and investments strategies employed by venture capitalists in the U.S. Investment of venture capitalists in telecommunication companies; Traditional measures of market readiness; Anticipation of the return of companies into the venture capital market.

  • The Big Money Comes From Outside the State. Taber, George M. // Business News New Jersey;2/25/2002, Vol. 15 Issue 9, p17 

    Reports the prevalence of outside sources in the capital venture business in New Jersey. Reference to the case of venture-capital firm Healthcare Ventures; Percentage of local venture capital funds; Profile of venture capital firms.

  • Financings Roundup.  // BioWorld Today;10/23/2008, Vol. 19 Issue 207, p5 

    The article reports that Series A financing helped Apitope Technology Ltd. to raise €10 million which will be used for conducting a Phase II trial of its ATXMS-1467 for multiple sclerosis (MS) treatment in 2009. The entry notes that the company will also be conducting advance programs for...

  • Investing in NH's Future. Sohl, Jeffrey // Business NH Magazine;Oct2009, Vol. 26 Issue 10, p27 

    The article reports on the caution of angel investors and venture capitalists in investing deals in New Hampshire in 2009. It states that the state has an amount of 25 venture capital deals in recent years, but less than 10% of the deals are at the start-up stage and vital seed. It says that...

  • Venture money streams in as investors look to deal.  // Long Island Business News (7/1993 to 5/2009);3/2/2007, Vol. 54 Issue 10, p17A 

    The article reports on the flow of cash as many venture capitalists invested $25.5 billion in 3,416 deals in 2006 in Long Island, New York. According to MoneyTree Report, these has resulted to a 10 percent increase in the number of deals and a 12 percent increase in dollar value. The year 2006...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics